We scan new podcasts and send you the top 5 insights daily.
Massive CFD simulation datasets can be distilled into compact reduced-order surrogate models of just a few megabytes using machine learning. Rather than sifting through overwhelming data files, the model interpolates between simulated test points to predict key bioreactor parameters—including kLa, shear rate distribution, and mixing times—in milliseconds for any given operating condition.
Instead of waiting for physical tech transfer runs, biotech startups can use CFD to determine whether a process refined in micro-bioreactors will run safely in a CDMO's specific reactor fleet. Performing this virtual scale-up in advance derisks facility selection, reduces timeline and financial commitments, and provides verifiable technical proof for prospective investors.
Because CFD operates strictly on physical parameters rather than biological mechanisms, a vessel needs to be fully characterized only once across 100 to 200 operational points. When switching to a new molecule, media, or cell line, the scale-up software only needs updated fluid properties such as viscosity, density, surface tension, and salt concentration, eliminating the need to re-run simulations from scratch.
By training on multi-scale data from lab, pilot, and production runs, AI can predict how parameters like mixing and oxygen transfer will change at larger volumes. This enables teams to proactively adjust processes, moving from 'hoping' a process scales to 'knowing' it will.
Modern cloud infrastructure allows teams to spin up hundreds of GPUs within seconds. Because these resources run in parallel, engineers can evaluate entire test matrices—spanning diverse stirring speeds, aeration rates, and fluid viscosities—in the exact same elapsed time that a single simulation would take, removing historical throughput bottlenecks.
Characterizing a bioreactor requires careful boundary setting because every additional variable exponentially increases the required simulation count. Adding wide continuum ranges for parameters like working volume or fluid viscosities creates an enormous operational space. Teams must strategically limit variables to discrete, sensible operating increments rather than attempting to model extreme spectrums from empty vessels to honey-like viscosities.
The most significant breakthroughs will no longer come from traditional wet lab experiments alone. Instead, progress will be driven by the smarter application of AI and simulations, with future bioreactors being as much digital as they are physical.
The future of bioprocess development involves using AI on high-throughput data for predictive modeling. This, combined with in silico simulations (digital twins), will allow scientists to understand underlying biological mechanisms, not just identify optimal conditions, dramatically accelerating optimization.
AI models mirror a bioreactor in real time, creating a "digital twin." This allows operators to test process changes and potential failure modes virtually, without touching the actual, expensive physical system, much like having a virtual engineer working alongside them.
Instead of running hundreds of brute-force experiments, machine learning models analyze historical data to predict which parameter combinations will succeed. This allows teams to focus on a few dozen targeted experiments to achieve the same process confidence, compressing months of work into weeks.
When deviations or disturbances occur in continuous bioprocessing, determining the exact volume of impacted material downstream is difficult. Through first-principle CFD and rapid response models across stirred tanks, connectors, filters, and chromatography units, teams can simulate the whole residence time distribution chain to pinpoint precisely which product must be discarded and which can be retained safely.